9-[(2-Hydroxyethoxy)
methyl] guanine (Acyclovir, Zovirax, ACV) is a selective antiviral agent against herpes simplex virus (HSV) -1 and -2 (Elion et al. 1977) . HSV is a common pathogen in AIDS patients and produces persistent ulcerative disease, which is usually responsive to ACV treatment.
However, chronic ACV therapy in AIDS patients leads to recurrent infection with an ACV-resistant HSV mutant, a problem that is increasingly common Erlick et al. 1989; Chatis and Crumpacker 1992) . While efforts are being made to develop a lipid prodrug of ACV that will be effective in treating TK-deficient HSV (Hostetler et al. 1993) , it is imperative to find a new agent that has potent activity, little toxicity, and preferably a different mechanism of action. Thus, it is important to pursue means of screening a large number of compounds with a rapid and sensitive assay system.
Cleavage of the tetrazolium salt, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT), into a blue-colored product (formazan) using the mitochondrial enzyme succinate-dehydrogenase (Slater et al. 1963 ) is potentially useful for screening antiviral compounds (Pauwels et al. 1988 ; Takeuchi et al. 1991; Hosoya et al. 1992) .
We have developed a rapid and accurate MTT assay system for screening antiviral agents against HSV-1 using L929 cells derived from mouse connective tissue. This system may be useful as an automatic screening system for the evaluation of anti-HSV-1 compounds.
MATERIALS AND METHODS

Cells
The L929 cells (NCTC clone 929, ATCC CCL 1) were purchased from Flow Laboratories, Inc. (Costa Mesa, CA, USA). The cells were grown in Eagle's minimal essential medium supplemented with 10% fetal calf serum (Cell Culture Laboratories, Cleveland, OH, USA), 100 units/ml penicillin G, and 100 ,u g/ml streptomycin.
For the viral infection, we used a maintenance medium in which the concentration of fetal calf serum was reduced to 2%.
Viruses
This study employed the KOS strain of HSV-1, a laboratory-stocked strain.
The KOS strain was propagated in L929 cells and stored at -80°C until used. 
Antiviral activity by the MTT method
The culture maintenance medium (62.5 )u 1) containing the maximum concentration of the test compound was added to the first row of the wells in flatbottomed, 96-well, microtiter trays (Falcon 3072, Becton Dickinson, Lincoln Park, NJ, USA), and 50 ,u 1 of the complete medium was added to the rest of the wells. Serial 5-fold dilutions were made directly in the microtiter tray using an eightchannel pipette. The last row of the wells was used for untreated controls.
The L929 cells were suspended in the maintenance medium at a concentration of 2 x 105 cells per ml and infected with HSV-1. Fifty microliters of mock-and virus-infected cell suspensions were then transferred into each well containing the dilution compound and were incubated for 4 days without change of the medium at 3TC in 5% CO2. After complete destruction of the virus-infected cells, 201al of MTT solution (7.5 mg/ml phosphate-buffered saline) was added to each well of the microtiter tray. The tray was then incubated at 37°C for 4 hr. Approximately 100,u1 of acidified isopropanol (2 ml of concentrated HC1 per 500 ml of isopropanol) containing 10% (vol/vol) Triton X-100 was added to each well to dissolve the formazan crystals. After shaking the tray for 10 min, whereby formazan crystals were completely dissolved, the absorbance of the wells was read in a computer-controlled microplate reader (Model 3550, Bio-Rad, Hercules, CA, USA) at two different wavelengths (540 and 690 nm).
The 50% cytotoxic concentration (CC50) of the test compound was defined as the concentration that reduced the absorbance of mock-infected cells to 50% of that of controls. The 50% antiviral effective concentration (EC50) was expressed as the concentration that achieved 50% protection of virus-infected cells from the HSV-induced destruction. The percent protection was calculated by the following formula:
where (ODT)Hsv is the absorbance of the test sample, (ODc)nsv is the absorbance of the virus-infected control (no compound), and (ODo)MocK is the absorbances of the mock-infected control. The ratio of (ODc)nsv to (ODc)MocK is expressed as "% of control". Antiviral assay by the plaque reduction method MRC-5 cells were seeded into a 24-well tissue culture plate (Falcon 3074, Becton Dickinson) at 2.0 x 105 cells/well and incubated at 3TC in 5% CO2. When the cell cultures were confluent, the growth medium was withdrawn and 0. 4 ml of virus suspension containing 100 pfu virus was added to each well. The plates were incubated at 37°C in 5% CO2 for 1 hr and washed once with the maintenance medium. Serial 5-fold dilutions of compounds in the maintenance medium were added (2 wells for each dilution). After 48 hr of incubation at 3T C, the cell sheet was fixed with 5% formalin and stained with 0.025% crystal violet. The number of HSV plaques was determined under a microscope (40 x).
RESULTS
Formazan formation in L929 cells
In the first experiment, we examined the formazan production in confluent L929 cells. Infection of L929 cells with HSV 1
In our search for a cell line, other than MRC-5 cells, that wohld be useful for evaluating anti-HSV compounds, we selected L929 cells due to their susceptibility to HSV-1. HSV-1 has been found to propagate rapidly in these cells. Fig. 2 shows the relationship between the OD value reflecting formazan formation and virus growth. Each cell culture was infected with 25 TCID50 of HSV-1 (KOS strain). The virus yield was monitored daily and compared with the OD values. Since the OD value decreased with the virus yield, the inhibition of formazan formation appears to reflect virus growth in the cells.
Inhibition of formazan formation in virus-infected cells
We examined the inhibition of formazan formation in HSV-1-infected L929 cells. The suspended L929 cells were infected with HSV-1 at 25 TCID50 (5.8 x 10-4 pfu/cell), 100 TCID50 (2.3 x 10-3 pfu/cell), and 200 TCID50 (4.6 x 10-3 pfu/ cell) (50% tissue culture infectious dose) per well and incubated at 37°C in 5% COZ. Fig. 3 shows the optical density of virus-infected L929 cells expressed as a ratio with that of mock-infected cells [(ODc)xsv/(ODc)MocK]. For the MTT assay, it is useful to reduce the ratio of virus-infected cells to mock-infected cells as much as possible. According to previous reports (Sudo et al. 1994 ), a value of 0.2 (80% inhibition of formazan formation in L929 cells by virus infection) is sufficient for determining anti-HSV activity. At 100 and 200 TCID50 HSV-1 levels, the OD value ratios were reduced to less than 0.2 at 3 days post-infection. At the 25 TCID50 level, a ratio of less than 0.2 was observed at 4 days. At a lower input dose (12.5 TCID50 ), more than 5 days of infection were required to reduce the OD ratio to less than 0.2.
We also examined the inhibition of formazan formation in confluent L929 cells infected with HSV-1. Fig. 4 shows that the ratio was reduced to less than 0.2 at 4 days at the 1,000 and 200 TCID50 levels, and at 5 days at the 100 TCID50 level. At the 25 TCID50 level, the ratio did not fall below 0.2 by 5 days postinfection. It was apparent that formazan formation in virus-infected cells was inhibited more rapidly when suspended cells were used for the HSV-1 infection. Table 1 shows the antiviral activity of ACV and BVaraU decided with an OD ratio of less than 0.2 in suspended cells infected with HSV-1. When the cultures were incubated with 200 or 100 TCID50 HSV-1, the EC50 values of ACV and BVaraU did not correspond to the results obtained by the plaque reduction method. However, when the cells were infected with 25 TCID50 HSV-1, the EC50 values of ACV and BVaraU were equivalent to the results determined by the plaque reduction method. Therefore, we used an infected level of 25 TCID50 for the experiment. were incubated for 5 days. Each point is the mean of six replicate wells.
Activity of anti-herpes compounds determined by the MTT method using L929 cells Several agents known to be potent inhibitors of HSV replication in vitro were evaluated for their inhibitory effect on cytopathogenicity for the KOS strain in L929 cells. The EC50 values of pyrimidine nucleoside analogs (IDU, BVDU, and BVaraU), purine nucleoside analogs (ACV, DHPG, and araA), and non-nucleoside compounds (PFA and dextran sulfate) were determined by the MTT assay, 4 days after HSV-1 infection of the L929 cells (25 TCID50/well), and by the plaque reduction method, using MRC-5 cells. As shown in Table 2 , the EC50 values DISCUSSION The use of a colorimetric assay for antiviral compounds offers major advantages in speed, simplicity, cost, and safety compared with conventional assays using the plaque reduction method. The MTT method for evaluating anti-HSV agents was established using MRC-5 cells of human embryonic lung fibroblast cell lines (Sudo et al. 1994 ). However, the MTT assay system with confluent MRC-5 cells cannot employ serial dilution of the test compound directly in a microtiter tray using a multichannel pipette, and the system is not rapid. Moreover, there is limit to the division of MRC-5 cells. Therefore, MRC-5 cells appear to be unsuitable for use in a continuous screening assay.
In the present study, we selected L929 cells because HSV-1 propagated rapidly in suspended cell culture of these cells. Ho et al. (1987) also assessed the antiviral activity of target-sensitive immunoliposome-encapsulated AraC and ACV using L929 cells infected with the HF strain of HSV-1. We developed the modified MTT method using L929 cells as follows: 1) since L929 cells are continuous cell strains, the MTT method was considered to be suitable for perpetual screening of anti-HSV agents; 2) it was found that the test compound could be diluted directly in a microtiter tray; and 3) incubation for 4 days was found to be sufficient for assessing antiviral activity, because virus-infected cell suspensions could be transferred into each well. However, since L929 cells were not infected with G strains of HSV-2, further studies should be conducted to identify cells suited to the evaluation of anti-HSV-2 activity.
Using the present MTT method, the EC50 and CC50 values were determined for a series of compounds already known as anti-HSV agents. All compounds were found to inhibit HSV-1 replication in L929 cells. The EC50 values obtained by the MTT method were equivalent to those obtained by the plaque reduction method with MRC-5 cells. In particular, the EC50 values of araA and BVaraU were determined by this MTT method even though they did not show anti-HSV activity on NC-37 cells or Vero cells (Suzutani et al. 1988 
